Process, tube and device for the preparation of wound healant composition

1. A composition comprising hyaluronic acid and at least one anticoagulant and at least one thixotropic gel, wherein said hyaluronic acid is layered beneath said thixotropic gel and/or wherein said thixotropic gel is layered beneath said anticoagulant.

2. The composition according to claim 1 , wherein said composition comprises hyaluronic acid, a thixotropic gel and an anticoagulant, wherein said hyaluronic acid is layered beneath said thixotropic gel and wherein said thixotropic gel is layered beneath said anticoagulant.

3. A centrifugation tube comprising a composition according to claim 2 .

4. An article of manufacture comprising the centrifugation tube of claim 3 .

5. The centrifugation tube according to claim 3 , wherein said centrifugation tube is:

a) a glass separator tube containing a polyester-based thixotropic gel, a buffered sodium citrate solution at 0.10 M and hyaluronic acid;

b) a polyethylene terephthalate separator tube containing a highly thixotropic gel formed by a polymer mixture, an anhydrous sodium citrate at 3.5 mg/m and hyaluronic acid,

c) a Cyclic Olefin Copolymer (COC) or Cyclic Olefin Polymer (COP) separator tube containing a polyester-based thixotropic gel, a buffered sodium citrate solution at 0.10 M and hyaluronic acid; or

d) a Cyclic Olefin Copolymer (COC) or Cyclic Olefin Polymer (COP) filter separator tube containing hyaluronic acid and a buffered sodium citrate solution at 0.10 M or an anhydrous sodium citrate at 3.5 mg/mL.

6. The composition according to claim 1 , wherein said composition further comprises:

a) enriched plasma and/or whole blood and/or bone marrow, and/or

b) a coagulation activator or thrombin serum, and/or

c) at least one cell extract, cell composition, tricalcium phosphate, bone substitute, chitosan, hyaluronic acid, cream, cream mask, fat cells, fat tissue, bone marrow concentrate, lubricin, cd-gelatin, botulinum toxin, calcium gluconate and/or stem cells,

wherein said cell extract is selected from an extract of: keratinocytes, bone marrow cells, osteoblasts, chondrocytes, fibroblasts, periosteum or corneal cells, melanocytes, Langerhans cells, fat cells, muscle cells, umbilical cord cells, mesenchymal stem cells (MSCs), preadipocytes, adipocytes, stem cells, periosteal cells, gingival cells, pre-endothelial cells, Schwann cells, ligament cells, tendon cells or pancreas islet cells.

7. The composition according to claim 6 , wherein the composition comprises:

a) plasma;

b) platelets at a concentration of at least 300×10 9 cells/L;

c) white blood cells at a concentration of at least 7×10 9 cells/L;

d) fibrinogen at a concentration of at least 3 mg/L;

e) optionally a coagulation activator or thrombin serum;

f) optionally at least one cell extract, cell composition, tricalcium phosphate (TCP), a bone substitute, chitosan, hyaluronic acid, cream, cream mask, fat cells, fat tissue, bone marrow concentrate, lubricin, cd-gelatin, botulinum toxin, calcium gluconate and/or stem cells,

wherein said cell extract is selected from an extract of: keratinocytes, bone marrow cells, osteoblasts, chondrocytes, fibroblasts, periosteum or corneal cells, melanocytes, Langerhans cells, fat cells, muscle cells, umbilical cord cells, mesenchymal stem cells (MSCs), preadipocytes, adipocytes, stem cells, periosteal cells, gingival cells, pre-endothelial cells, Schwann cells, ligament cells, tendon cells or pancreas islet cells.

8. The composition according to claim 7 , wherein the muscle cells are selected from myoblasts and satellite cells.

9. The composition according to claim 6 , wherein the thrombin serum, enriched plasma, cell composition, stem cells, fat cells, fat tissue, hone marrow concentrate and/or cell extract is autologous.

10. A method of treating a subject comprising administering a composition according to claim 6 to a wound, damaged tissue, damaged bone, a periodontal defect or cavity or the skin of a subject.

11. The composition according to claim 6 , wherein the muscle cells are selected from myoblasts and satellite cells.

12. The composition according to claim 1 , wherein said anticoagulant is selected from anyhirudin, benzylsulfonyl-d-Arg-Pro-4-amidinobenzylamide (BAPA), heparin, sodium citrate, citrate, acid citrate dextrose (ACD), citrate-theophylline-adenosine-dipyridamole (CTAD), potassium-ethylenediaminetetraacetic acid (EDTA) or a combination thereof.

13. A container comprising a composition according to claim 1 .

14. The container according to claim 13 , wherein said container is a centrifugation tube.

15. The centrifugation tube according to claim 14 , wherein the centrifugation tube comprises the layer of hyaluronic acid, the layer of the thixotropic gel and the layer of anticoagulant, wherein the layers of hyaluronic acid, thixotropic gel and anticoagulant migrate across each other upon centrifugation of the centrifugation tube.

16. The container according to claim 13 , wherein said hyaluronic acid is at the bottom of said container and comprises about 1 ml to about 2 ml of hyaluronic acid.

17. The container according to claim 13 , comprising about 1 ml to about 2 ml of hyaluronic acid, about 2 g of thixotropic gel and about 1 ml of sodium citrate at 0.109M.

18. The container according to claim 13 , wherein said container:

i) has an inlet for introducing whole blood; and/or

ii) is held in a vacuum intended to aspirate a whole blood sample; and/or

iii) is sterile; and/or

iv) has a usable vacuum of or about 8 to about 10 mL; and/or

v) is suitable for undergoing centrifugation; and/or

vi) is sealed; and/or

vii) is manipulated entirely in closed circuit.

19. An article of manufacture comprising the container of claim 13 .

20. The article of manufacture according to claim 19 , wherein:

a) said article of manufacture is a medical device or kit;

b) said anticoagulant is sodium citrate; and

c) said container is a tube.

21. An article of manufacture comprising a composition according to claim 1 within a container.

22. The article of manufacture according to claim 21 , wherein said anticoagulant is sodium citrate and said container is a tube wherein said container comprises hyaluronic acid at the bottom of said tube followed by said thixotropic gel which is followed by said anticoagulant.

23. The article of manufacture according to claim 21 , said composition within the container further comprising whole blood.

24. The article of manufacture according to claim 21 , said composition within the container comprising hyaluronic acid and enriched plasma.

25. The article of manufacture according to claim 21 , wherein:

a) said article of manufacture is a medical device or kit;

b) said anticoagulant is sodium citrate; and

c) said container is a tube.